Emerging therapies for dry eye disease

Area of Science:

• Ophthalmology
• Immunology
• Pharmacology

Background:

• Dry Eye Disease (DED) is a prevalent, multifactorial ocular surface condition.
• It involves tear film instability and a cycle of ocular surface inflammation.
• Current treatments for DED are often inadequate for patients.

Purpose of the Study:

• To review the burden, pathophysiology, and emerging therapies for Dry Eye Disease.
• To discuss the mechanisms, development phases, and clinical trial results of novel DED treatments.
• To highlight the need for improved DED therapies with better bioavailability and fewer side effects.

Main Methods:

• Comprehensive literature search using PubMed, Cochrane Library, Web of Science, ClinicalTrials.gov, and Springer AdisInsight.
• Review focused on emerging therapies including immunosuppressants, immunomodulators, anti-inflammatory drugs, and corticosteroids.
• Analysis of drug mechanisms, development status, and recent clinical trial data for DED treatments.

Main Results:

• Several promising therapeutic classes are emerging for DED management.
• These include immunosuppressants, immunomodulators, and anti-inflammatory agents targeting the ocular surface.
• Ongoing research focuses on optimizing drug delivery and efficacy for DED.

Conclusions:

• The ideal DED therapy requires improved bioavailability, minimal side effects, and effective dosing.
• Targeting the inflammation cascade and establishing objective severity markers are crucial for advancing DED treatment.
• Promising novel therapies are under development to address the unmet needs in Dry Eye Disease management.